Malmasi, A., Ziaie Ardestani, B., Mohebali, M., Akhoundi, B., Ziaie, S., Masoudifard, M., Khorram Khorshid, H., Nassiri, M., Bayanolhagh, S., Mostafavi, E., Delrobai, M., Siavashi, V. (2014). Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis. Iranian Journal of Pharmaceutical Research, 13(4), 1357-1367.
Abdolali Malmasi; Bijan Ziaie Ardestani; Mehdi Mohebali; Behnaz Akhoundi; Shadi Ziaie; Majid Masoudifard; Hamidreza Khorram Khorshid; Mehdi Nassiri; Saeed Bayanolhagh; Ehsan Mostafavi; Moin Delrobai; Vahid Siavashi. "Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis". Iranian Journal of Pharmaceutical Research, 13, 4, 2014, 1357-1367.
Malmasi, A., Ziaie Ardestani, B., Mohebali, M., Akhoundi, B., Ziaie, S., Masoudifard, M., Khorram Khorshid, H., Nassiri, M., Bayanolhagh, S., Mostafavi, E., Delrobai, M., Siavashi, V. (2014). 'Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis', Iranian Journal of Pharmaceutical Research, 13(4), pp. 1357-1367.
Malmasi, A., Ziaie Ardestani, B., Mohebali, M., Akhoundi, B., Ziaie, S., Masoudifard, M., Khorram Khorshid, H., Nassiri, M., Bayanolhagh, S., Mostafavi, E., Delrobai, M., Siavashi, V. Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis. Iranian Journal of Pharmaceutical Research, 2014; 13(4): 1357-1367.
Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis
1Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
2Department of Parasitology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Sciences, Tehran, Iran.
3Department of Parasitology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
4Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid-Beheshti University of Medical Sciences, Tehran, Iran.
5Genetic Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
6Iranian Research Center for HIV/AIDs (IRCHA), Tehran University of Medical Sciences, Tehran, Iran.
7Department of Epidemiology, Pasteur institute of Iran, Tehran, Iran.
8Department of Biochemistry, Faculty of Basic sciences, University of Gilan, Rasht, Iran.
Abstract
Toxicity and drug resistance against pentavalent antimonials, medications of choice in treatment of leishmaniasis for more than 5 decades, have become important subjects globally. This study was a randomized, open labeled trial that was designed to determine efficacy and safety of IMOD as a novel herbal immunomodulator drug for treatment of canine visceral leishmaniasis (CVL). Twenty healthy mongrel dogs were infected with Iranian strain of L. Infantum amastigotes and randomly divided to 5 groups with four animals for each included on: I: negative control (non-infected) II: Glucantime® III: Glucantime® plus IMOD (immune-chemotherapy) IV: IMOD and V: positive control (non-treated). Physical examination, hematological, biochemical, serological, parasitological, pathological and imaging evaluations were performed pre-/post- interventions every month for 3 months. Comparing with control groups (I&V), immune-chemotherapy group (Glucantime® plus IMOD) showed significantly higher efficacy in resolving the clinical signs and hematobiochemistry factors. Based on our results, using IMOD in combination with meglumine antimoniate (Glucantime®) has significantly improved CVL than the latter drug alone. So, it seems this new herbal medicine is useful as adjuvant therapy for canine visceral leishmaniasis.
Top